Arqule (ARQL) Stock Price & Overview
NASDAQ:ARQL
Current stock price
The current stock price of ARQL is 20 null. Today ARQL is up by 0.15%. In the past month the price decreased by -0.6%. In the past year, price increased by 434.76%.
ARQL Key Statistics
- Market Cap
- 2.417B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.34
- Dividend Yield
- N/A
ARQL Stock Performance
ARQL Stock Chart
ARQL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ARQL. When comparing the yearly performance of all stocks, ARQL is one of the better performing stocks in the market, outperforming 99.67% of all stocks.
ARQL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARQL. ARQL has a great financial health rating, but its profitability evaluates not so good.
ARQL Earnings
ARQL Forecast & Estimates
ARQL Financial Highlights
Over the last trailing twelve months ARQL reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS decreased by -112.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -808.06% | ||
| ROA | -21.4% | ||
| ROE | N/A | ||
| Debt/Equity | 0.08 |
ARQL Ownership
About ARQL
Company Profile
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Company Info
Arqule
ONE WALL STREET
BURLINGTON MA 01803
CEO: Paolo Pucci
Phone: 781-994-0300
Arqule / ARQL FAQ
Can you describe the business of Arqule?
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
What is the stock price of Arqule today?
The current stock price of ARQL is 20 null. The price increased by 0.15% in the last trading session.
Does ARQL stock pay dividends?
ARQL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARQL stock?
ARQL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for Arqule?
Arqule (ARQL) has a market capitalization of 2.42B null. This makes ARQL a Mid Cap stock.